Normal view MARC view ISBD view

Patterns of preventive dental behavior. [electronic resource]

By:

Swank, M E

Contributor(s):

Producer: 19860512Description: 175-84 p. digitalISSN:

0033-3549

Subject(s):

In: Public health reports (Washington, D.C. : 1974) vol. 101

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article; Review

There are no comments on this title.

to post a comment.

Back to results

421 Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
by Hsiang, Kuo-Wei
422 Effects of preemptive analgesia in laparoscopic cholecystectomy: a double-blind randomized controlled trial.
by Sandhu, Trichak
423 Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
by Andersohn, Frank
424 Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies.
by Micu, Mihaela C
425 The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
by Hunt, Richard H
426 Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
by Walter, B
427 Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
by Uwai, Yuichi
428 Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
by Bingham, C O
429 Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?
by Brunnekreef, Jaap J
430 Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.
by Gottesdiener, K
431 COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
by Hochberg, Marc C
432 An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin.
by Schaffler, Klaus
433 Altered membrane lipid dynamics and chemoprevention by non-steroidal anti inflammatory drugs during colon carcinogenesis.
by Singh Kanwar, S
434 Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
by Riendeau, D
435 Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal.
by Song, Gwan Gyu
436 The use of etoricoxib and celecoxib for pain prevention after periodontal surgery: a double-masked, parallel-group, placebo-controlled, randomized clinical trial.
by Steffens, Joao Paulo
437 Thermoresponsive polymeric gel as an on-demand transdermal drug delivery system for pain management.
by Indulekha, S
438 Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
by Zimmer, Lisa
439 Nuclear factor kappa B: a pro-inflammatory, transcription factor-mediated signalling pathway in lung carcinogenesis and its inhibition by nonsteroidal anti-inflammatory drugs.
by Setia, Shruti
440 Evaluation of a single preoperative dose of etoricoxib for postoperative pain relief in therapeutic knee arthroscopy: a randomized trial.
by Lierz, Peter